Wenchao Bian

Wenchao Bian


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
LZLing Zhang
Ling Zhang
HLHaifeng Li
Haifeng Li
TWTao Wang
Tao Wang
ZWZhu Wang
Zhu Wang
YWYang Wu
Yang Wu
JYJianqiang You
Jianqiang You
Objective: The purpose was to evaluate the relationship between peripheral eosinophilia, Japan Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC) score, and olfactory dysfunction in chronic rhinosinusitis (CRS) patients and to explore the accuracy and specific cut points of the JESREC score in predicting olfactory dysfunction.Methods: In this cross-sectional, retrospective study, olfactory function was assessed by the Sniffin’ Sticks 12-item test and multivariate logistic regression analyses were carried out. Receiver operating characteristic curves were plotted to derive accuracy and cutoff values for the JESREC scores of the olfactory dysfunction criterion.Results: A total of 354 patients [mean (SD) age, 50.0 (14.9) years; 41.8% women] were included in the final analysis. The prevalence of olfactory dysfunction was 46.3%. Individuals who had olfactory dysfunction were more likely to be male (64.6% vs. 52.6%), have eosinophilic chronic rhinosinusitis (ECRS) (39.0% vs. 7.9%), have a longer course of CRS (2.3 years vs. 1.5 years), have higher JESREC scores (8.5 vs. 4.5), and have higher proportions of nasal polyps (78.7% vs. 18.9%) and peripheral eosinophilia (3.3% vs. 1.4%). In logistic analysis, the percentage of eosinophils (1.25, 1.13–1.37), JESREC score (1.31, 1.22–1.40), bilateral lesion (2.06, 1.25–3.41), nasal polyps (15.83, 9.23–27.16), CT shadow (2.73, 1.69–4.43), and ECRS (6.86, 3.68–12.80) were associated with olfactory dysfunction in CRS patients after controlling for covariates, while peripheral neutrophils were not significant. In addition, the area under the curve was 0.778 and the cutoff value for JESREC score for olfactory dysfunction was defined as 5.5.Conclusions: Peripheral eosinophilia and high JESREC scores were significantly associated with the risk of olfactory dysfunction in CRS patients, and special attention should be paid to patients with a JESREC score ≥6.

6 August 2024 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
WLWenjing Li
Wenjing Li
JYJianqiang You
Jianqiang You
WBWenchao Bian
Wenchao Bian
YLYi Liu
Yi Liu
JCJunjun Chen
Junjun Chen
CWChangping Wu
Changping Wu
Background HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) represents a recently identified member of the B7 immune checkpoint family, characterized by limited expression in normal tissues but notable overexpression in various cancer types. Nevertheless, the precise function and interaction with immune cells remain poorly understood, particularly in laryngeal squamous cell carcinoma (LSCC). This investigation endeavored to elucidate the biological significance of HHLA2 within the tumor microenvironment of human LSCC tissues and delineate the clinical relevance and functional roles of HHLA2 in LSCC pathogenesis. Methods Through multiplexed immunohistochemistry analyses conducted on tissue microarrays sourced from LSCC patients (n = 72), the analysis was executed to assess the expression levels of HHLA2, density and spatial patterns of CD68+HLA-DR+CD163− (M1 macrophages), CTLA-4+CD4+FoxP3+ (CTLA-4+Treg cells), CTLA-4+CD4+FoxP3− (CTLA-4+Tcon cells), exhausted CD8+T cells, and terminally exhausted CD8+T cells in LSCC tissues. Survival analysis was conducted to evaluate the prognostic significance of HHLA2 and these immune checkpoints or immune cell populations, employing COX regression analysis to identify independent prognostic factors. Results Kaplan–Meier (K–M) survival curves revealed a significant association between HHLA2 expression and overall survival (OS) in LSCC. Elevated levels of HHLA2 were linked to reduced patient survival, indicating its potential as a prognostic marker (HR: 3.230, 95%CI 0.9205–11.34, P = 0.0067). Notably, increased infiltration of CD68+ cells (total macrophages), STING+CD68+HLA-DR+CD163− (STING+M1 macrophages), CTLA-4+CD4+FoxP3+, CTLA-4+CD4+FoxP3−, PD-1+LAG-3+CD8+T cells, and PD-1+LAG-3+TIM-3+CD8+T cells strongly linked to poorer survival outcomes (P < 0.05). A discernible trend was observed between the levels of these immune cell populations, STING+CD68+ (STING+ total macrophages), CD68+HLA-DR+CD163−, STING+CD68+CD163+HLA-DR− (STING+M2 macrophages), PD-1+LAG-3−CD8+T cells, PD-1+TIM-3+CD8+T cells, and PD-1+LAG-3+TIM-3−CD8+T cells and prognosis. Importantly, multivariate COX analysis identified HHLA2 as an independent predictive factor for OS in LSCC patients (HR = 3.86, 95% CI 1.08–13.80, P = 0.038). This underscored the potential of HHLA2 as a critical marker for predicting patient outcomes in LSCC. Conclusions HHLA2 emerged as a detrimental prognostic biomarker for assessing OS in LSCC patients. Relative to other immune checkpoints, HHLA2 exhibited heightened predictive efficacy for the prognosis of LSCC patients.

11 September 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
LZLing Zhang
Ling Zhang
WBWenchao Bian
Wenchao Bian
LXLei Xi
Lei Xi
JYJianqiang You
Jianqiang You
Background: Chronic Rhinosinusitis (CRS), particularly its eosinophilic endotype (ECRS), is frequently associated with comorbid lower airway diseases. The JESREC score is a clinical tool for predicting ECRS. This study aimed to evaluate the association between the JESREC score and pulmonary dysfunction in adult CRS patients and to explore the potential role of metabolic factors. Methods: Patients were categorized based on pulmonary function tests and multivariate logistic regression analyses were performed to identify associated factors for overall pulmonary dysfunction and its restrictive and obstructive subtypes. The discriminative ability of the JESREC score was evaluated using Receiver Operating Characteristic (ROC) curve analysis. Furthermore, mediation models were constructed to figure out the mediating role of metabolic factors (BMI, blood pressure, fasting blood glucose and serum lipidomic profiles). Results: A total of 143 patients were included in the final analysis. The JESREC score was significantly higher in patients with pulmonary dysfunction (8.6 vs. 5.0, P < 0.001). Multivariate analysis confirmed the JESREC score (OR, 1.24, 95% CI, 1.12–1.37) and ECRS (5.17, 2.05–13.09) as associated factors for pulmonary dysfunction, including both restrictive and obstructive subtypes. The ROC curve showed an AUC of 0.729, with an optimal JESREC cutoff of 4.5. Mediation analysis indicated that systolic blood pressure, diastolic blood pressure, triglycerides, and HDL-C significantly mediated 6.4%, 4.5%, 8.4%, and 6.5% of the total effect, respectively. Conclusions: JESREC score was independently associated with pulmonary dysfunction in CRS patients, and metabolic factors may statistically mediate part of this association, suggesting a potential pathway. Furthermore, patients with JESREC score ≥ 5 may warrant special attention to pulmonary function.

2 November 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YXYingxin Xia
Yingxin Xia
ZHZhenglin He
Zhenglin He
XWXiaoye Wang
Xiaoye Wang
WBWenchao Bian
Wenchao Bian
Epstein–Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) contains several overlapping DNA pools, including viral DNA, tumor-derived nuclear DNA, mitochondrial DNA (mtDNA), neutrophil extracellular trap (NET) chromatin, and DNA released during treatment. These materials have usually been studied separately—as biomarkers, danger signals, or treatment-associated DNA species. We use the term extracellular DNA (exDNA) ecology to connect DNA source and molecular state with carrier, compartment, recipient cell, sensing route, clearance, and time. NPC studies provide several mechanistic anchors. Radiotherapy-associated mitochondrial injury can activate cGAS–STING and support type I interferon and CD8+ T-cell immunity, whereas mtDNA sensing in chemotherapy-induced senescent NPC cells can drive an NF-κB–IL-35 program that suppresses natural killer cells. Gemcitabine–cisplatin-generated DNA fragments can coordinate tumor-cell STING with B-cell TLR9, and EBV-derived BRRF2-positive extracellular vesicles can reduce macrophage cGAS competence. Several of these studies, however, map intracellular DNA generation or mitochondrial-to-cytosolic release without demonstrating extracellular transit. We therefore treat those events as upstream inputs to a possible extracellular route. An acute-to-persistent shift is proposed here as a testable working model, not as an established longitudinal sequence. Carrier state and recipient-cell identity may add information beyond DNA concentration alone. For clinical translation, plasma EBV DNA remains the most mature measurement, and early clearance after induction chemotherapy provides a practical setting in which molecular-state and immune-context readouts can be tested prospectively.